Prescription Required.Why?
Is the active ingredient.
Treatment of idiopathic pulmonary fibrosis (IPF) in adults.
Treatment of systemic sclerosisassociated interstitial lung disease (SSc-ILD) in adults.
Nindanib 100 Cap (Nintedanib) is a tyrosine kinase inhibitor that selectively inhibits the activity of fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor receptors (VEGFRs), and platelet-derived growth factor receptors (PDGFRs). By blocking these receptors, nintedanib reduces the proliferation and migration of fibroblasts and other cells involved in the pathogenesis of IPF and SSc-ILD, thereby slowing disease progression.
Store below 25°C (77°F). Protect from moisture.
The recommended dose of nintedanib is 150 mg twice daily, taken with food.
The capsules should be swallowed whole with water; do not crush, chew or open them.
Dosage adjustments may be necessary based on individual patient factors such as liver and kidney function.
Diarrhea
Nausea
Vomiting
Weight loss
Fatigue
Increased liver enzymes
Decreased appetite
Hair thinning
Rash
Elevated blood pressure
Alcohol consumption may increase the risk of side effects. Limit or avoid alcohol while taking nintedanib.
Nintedanib may cause dizziness, fatigue or vision changes. Avoid driving or operating machinery if affected.
Nintedanib is contraindicated in pregnancy. Effective contraception is essential. It is also contraindicated during breastfeeding.
The safety and efficacy of nintedanib in children have not been established.
Dosage adjustment may be necessary for patients with impaired kidney function.
Dosage adjustment may be necessary for patients with impaired liver function. Regular liver function monitoring is recommended.
Please consult your physician or pharmacist for specific references and complete prescribing information.
The official prescribing information (package insert) for the specific nintedanib product you are taking should be reviewed.
